Issue Date: October 3, 2016
Genentech gets cancer drug from Hanmi
Genentech has licensed a small-molecule oncology treatment from the South Korean drug company Hanmi Pharmaceutical. Genentech will pay $80 million up front and up to $830 million in milestone payments for worldwide rights, except in South Korea, to HM95573, a pan-RAF inhibitor that is in Phase I clinical trials. RAF kinases are mitogen-activated protein kinases that are known to be associated with various cancers. Genentech says it has worked in this area for 25 years.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society